Effect of tamoxifen on postmenopausal endometrium

Area of Science:

• Gynecology
• Oncology
• Pathology

Background:

• Tamoxifen is a widely used endocrine therapy for hormone receptor-positive breast cancer.
• Its long-term use in postmenopausal women necessitates monitoring for potential gynecological side effects.
• Endometrial changes are a known concern associated with tamoxifen treatment.

Purpose of the Study:

• To evaluate the effects of tamoxifen on the endometrium in postmenopausal women with breast cancer.
• To assess the utility of hysteroscopy, ultrasound, and histology in detecting tamoxifen-induced endometrial changes.
• To investigate the expression of Bcl-2 and Ki67 in relation to endometrial pathology.

Main Methods:

• Studied 45 postmenopausal women with breast cancer on tamoxifen therapy for 6-48 months.
• Utilized hysteroscopy, ultrasound, histological examination, and immunohistochemistry (Bcl-2, Ki67).
• Compared findings in patients with thickened endometrium, suspected polyps, or postmenopausal bleeding.

Main Results:

• Ultrasound revealed thickened endometria (18/45), suspected polyps (14/45), and fluid accumulation (1/45).
• Histology showed adenomatous polyps (23/45), cystic atrophy (15/45), hyperplasia (2/45), and adhesions (5/45).
• Elevated Bcl-2 and Ki67 expression were observed in polyps and hyperplasia, indicating increased cell proliferation.

Conclusions:

• Long-term tamoxifen therapy is linked to significant uterine pathology in postmenopausal women.
• Ultrasonography is useful for screening asymptomatic patients with thickened endometria.
• Hysteroscopy provides accurate diagnosis and allows targeted biopsies for endometrial disease assessment.